Resolve mdx
for Urinary Tract Infection

SAMPLE
Patient Report

Patient
Patient Name: Jane Doe
Date of Birth: 02-22-1952
MRN/Patient #: 1234-1

Specimen
Specimen #: 123-456-789
Collection Date: 10-07-2025
Received Date: 10-08-2025
Report Date: 10-09-2025
Specimen Type: Clean catch urine
Mdxhealth Accession #: A00000

Account
Physician: Dr. Smith
Account: Urology Care
Address: 12345 Alton
City, State, Zip: Irvine, CA 92618

PATIENT RESULT: PATHOGEN(S) DETECTED

Pathogen(s) Detected

Pathogen(s) Detected	Copies/mL
Enterococcus faecalis	4.36×10^6
Escherichia coli	9.56×10^5

Resistance Gene(s) Detected

Resistance Gene(s) Detected	Antimicrobial Resistance
Trimethoprim/Sulfamethoxazole	Trimethoprim-sulfamethoxazole

Patient Susceptible Antimicrobials

- Amoxicillin-clavulanate PO
- Fosfomycin PO
- Nitrofurantoin PO
- Doxycycline PO/IV
- Minocycline PO/IV
- Moxifloxacin PO/IV
- Tetracycline PO/IV
- Ampicillin PO/IM/IV
- Ampicillin-sulbactam IV
- Piperacillin-tazobactam IV

Patient Susceptibility Report

Report Key
S = Susceptible I = Intermediate R = Resistant
SDD = Susceptible-Dose Dependent *R = Data not patient specific
N/A = Detected organism has variable results SNP = Susceptibility not performed

Antimicrobial	Formulation	Antimicrobial Phenotypic Susceptibility	Supportive Data (not patient specific)	
			Escherichia coli	Enterococcus faecalis
Amoxicillin-clavulanate	PO	S	✓	✓
Fosfomycin	PO	S	✓	✓
Nitrofurantoin	PO	S	✓	✓
Doxycycline	PO/IV	S	✓	✓
Minocycline	PO/IV	S	✓	✓
Moxifloxacin	PO/IV	S	✓	✓
Tetracycline	PO/IV	S	✓	✓
Ampicillin	PO/IM/IV	S	✓	✓
Ampicillin-sulbactam	IV	S	✓	✓
Piperacillin-tazobactam	IV	S	✓	✓
Levofloxacin	PO/IV	I	✓	✓
Tobramycin	IM/IV	I	✓	✓
Cefdinir	PO	R		✓

Antimicrobial	Formulation	Antimicrobial Phenotypic Susceptibility	Supportive Data (not patient specific)	
			Escherichia coli	Enterococcus faecalis
Cephalexin	PO	R		✓
Linezolid	PO	R	✓	
Ciprofloxacin	PO/IV	R	✓	✓
Trimethoprim-sulfamethozazole	PO/IV	R		✓
Cefazolin	IM/IV	R		✓
Cefepime	IM/IV	R		✓
Cefoxitin	IM/IV	R		✓
Ceftriaxone	IM/IV	R		✓
Gentamicin	IM/IV	R	✓	✓
Aztreonam	IV	R		✓
Vancomycin	IV	R	✓	
Ofloxacin	PO/IM/IV	N/A	✓	✓
Meropenem	IV	N/A	✓	✓

COMMENT:
N/A

RESISTANCE GENE(S) - NOT DETECTED:
Carbapenem (CRE) Resistant, Extended Spectrum Beta-Lactamase (ESBL), Fluoroquinolone, Methicillin Resistance (mecA), Mobilized Colistin Resistance, Vancomycin Resistant (VRE),

PATHOGEN(S) - NOT DETECTED:

BACTERIA:

- **Acinetobacter baumannii**
- **Actinotignum schaalii**
- **Citrobacter freundii**
- **Citrobacter koseri**
- **Enterobacter cloacae**
- **Enterococcus faecium**
- **Klebsiella aerogenes**
- **Klebsiella oxytoca**
- **Klebsiella pneumoniae**
- **Morganella morganii**
- **Mycoplasma genitalium**
- **Mycoplasma hominis**
- **Proteus mirabilis**
- **Serratia marcescens**
- **Staphylococcus aureus**
- **Staphylococcus saprophyticus**
- **Streptococcus agalactiae**
- **Streptococcus pyogenes**
- **Ureaplasma parvum**
- **Ureaplasma urealyticum**

YEAST:

- **Candida albicans**
- **Candida auris**
- **Candida glabrata**
- **Candida krusei**
- **Candida parapsilosis**

Information About the Patient Susceptibility Report:
Gray checkmarks indicate there is supportive evidence that the antibiotic, either FDA approved or off label, can be used for treatment. Treatment options are not intended to be prescriptive for any specific patient. Appropriate medical judgment should be exercised by the attending physician before prescribing a course of treatment.

N/A displayed on the report indicates there is no FDA-approved interpretation guidelines for the applicable organism-antimicrobial combination. Refer to supportive data in the table for possible antimicrobial use in these instances.

Methodology and Clinical Significance:
Pathogens and Resistance Genes are detected through real time multiplex PCR. All pathogens are quantified via DNA copies per milliliter of urine based on a limit of detection of 10^3. Resistance genes are reported as “detected” or “not detected” when applicable pathogens are detected. Antimicrobial susceptibility is determined by testing the whole urine polymicrobial population against a panel of antimicrobial agents. Antimicrobial susceptibility testing is only performed on non-fastidious bacteria. Please visit mdxhealth.com/resolvemethodology for more information.

Disclaimer:
Mdxhealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as an accredited laboratory to perform high complexity clinical testing. The Resolve mdx test was developed, and its performance characteristics determined by mdxhealth. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined such clearance or approval is not necessary. Use outside of this indication has not been validated by mdxhealth. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician and relevant guidelines on the decision for Urinary Tract Infection**.**

This test was performed by Delta Laboratories LLC dba mdxhealth Central, 7000 Preston Road, Suite 1500, Plano, TX 75024.
CLIA# 45D2229819; CAP# 9356578.

Joseph L. Sailors, M.D.

Joseph L. Sailors, MD, Laboratory Director

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

mdxhealth

Mdxhealth • 15279 Alton Parkway, Suite 100, Irvine, CA 92618 • P: 866.259.5644 • F: 949.788.0014 • E: cs@mdxhealth.com • www.mdxhealth.com